Zika virus anti-WNV antibodies antibody-dependent enhancement (ADE) cross-reactive antibodies intravenous immunoglobulin (IGIV)

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
30 Apr 2024
Historique:
medline: 30 4 2024
pubmed: 30 4 2024
entrez: 30 4 2024
Statut: aheadofprint

Résumé

Human immunoglobulin preparations contain a diverse range of polyclonal antibodies that reflect past immune responses against pathogens encountered by the blood donor population. In this study, we examined a panel of intravenous immunoglobulins (IGIVs) manufactured over the past two decades (1998-2020) for their capacity to neutralize or enhance Zika virus (ZIKV) infection

Identifiants

DOI: 10.1128/spectrum.00758-24 PMID: 38687079
pubmed: 38687079
doi: 10.1128/spectrum.00758-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0075824

Auteurs

Yong He (Y)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Lilin Zhong (L)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Hailing Yan (H)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Maria Luisa Virata (ML)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID: 0000-0002-5559-5174

Lu Deng (L)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Ashish K Mishra (AK)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Evi Struble (E)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Dorothy Scott (D)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Pei Zhang (P)

Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID: 0000-0002-0572-2614

Classifications MeSH